SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May. 31, 2012--
Exelixis, Inc. (NASDAQ: EXEL) announced today that Michael M. Morrissey,
Ph.D., the company’s president and chief executive officer, will present
at the Goldman Sachs 33rd Annual Global Healthcare Conference
at 12:20 p.m. EDT / 9:20 a.m. PDT on Wednesday, June 6, 2012, in Rancho
Palos Verdes, California. During the presentation, Dr. Morrissey will
discuss the company’s development program and plans for cabozantinib,
and review the most recent publicly available data for the compound,
including data presented at the 2012 ASCO Annual Meeting. He will also
provide a general business update.
The presentation will be webcast and may be accessed via the Event
Calendar page under Investors at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on
cabozantinib (XL184), its most advanced product candidate, in order to
maximize the therapeutic and commercial potential of this compound.
Exelixis believes cabozantinib has the potential to be a high-quality,
broadly-active, differentiated pharmaceutical product that can make a
meaningful difference in the lives of patients. Exelixis has also
established a portfolio of other novel compounds that it believes have
the potential to address serious unmet medical needs, many of which are
being advanced by partners as part of collaborations. For more
information, please visit the company's web site at http://www.exelixis.com.
Source: Exelixis, Inc.
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor Relations and
Corporate Communications
cbutler@exelixis.com
